



100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

ELEMENTAL IMPURITY ASSESSMENT

MATERIAL NAME: 6N HCl IN IPA (FORMOSA GAS)

Table 1: Elemental Impurity Risk Assessment		Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)	
Element	Class	¹ Limits 1.0J Target ppm (µg/g)	Limits 0.1J Method LOQ ppm (µg/g)
Cadmium (Cd)	1	0.20	0.02
Lead (Pb)	1	0.50	0.05
Arsenic (As)	1	1.5	0.15
Mercury (Hg)	1	0.30	0.03
Cobalt (Co)	2A	0.50	0.05
Vanadium (V)	2A	1.0	0.10
Nickel (Ni)	2A	2.0	0.20
Thallium (Tl)	2B	0.80	0.08
Gold (Au)	2B	10	1.0
Palladium (Pd)	2B	1.0	0.10
Iridium (Ir)	2B	1.0	0.10
Osmium (Os)	2B	1.0	0.10
Rhodium (Rh)	2B	1.0	0.10
Ruthenium (Ru)	2B	1.0	0.10
Selenium (Se)	2B	8.0	0.80
Silver (Ag)	2B	1.0	0.10
Platinum (Pt)	2B	1.0	0.10

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

Table 1: Elemental Impurity Risk Assessment		Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)	
Element	Class	¹Limits 1.0J Target ppm (µg/g)	Limits 0.1J Method LOQ ppm (µg/g)
Lithium (Li)	3	25	2.5
Antimony (Sb)	3	9.0	0.90
Barium (Ba)	3	70	7.0
Molybdenum (Mo)	3	150	15
Copper (Cu)	3	30	3.0
Tin (Sn)	3	60	6.0
Chromium (Cr)	3	110	11
Calcium (Ca)	4	50	5.0
Iron (Fe)	4	3.0	0.30
Sodium (Na)	4	50	5.0

¹Limits derived from Analytical Method BSI-ATM-0087

TABLE 2: ELEMENTAL IMPURITY ASSESSMENT				Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)			
Element	Limits 1.0J Target ppm (µg/g)	Result IPA RM Lot: RMAT-0422- 0059 ppm (µg/g)	Result IPA RM Lot: RMAT-0522- 0002 ppm (µg/g)	Result IPA RM Lot: RMAT-0722- 0056 ppm (µg/g)	Result IPA RM Lot: RMAT-1022- 0029 ppm (µg/g)	Result RM Lot: IHCL-0122- 00013-PV Reprocessed ppm (µg/g)	Result IP Lot: IHCL-0122- 00013-PV Confirmation #2 Sample ppm (µg/g)
Cd	0.20	<0.02	<0.02	<0.02	<0.02	<0.02	<0.02
Pb	0.50	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
As	1.5	<0.15	<0.15	<0.15	<0.15	<0.15	<0.15
Hg	0.30	<0.03	<0.03	<0.03	<0.03	<0.03	<0.03
Co	0.50	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
V	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ni	2.0	<0.20	<0.20	<0.20	<0.20	0.28	0.58
Tl	0.80	<0.08	<0.08	<0.08	<0.08	<0.08	<0.08
Au	10	<1.0	<1.0	<1.0	<1.0	<1.0	<1.0
Pd	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ir	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Os	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Rh	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ru	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Se	8.0	<0.80	<0.80	<0.80	<0.80	<0.80	<0.80

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

TABLE 2: ELEMENTAL IMPURITY ASSESSMENT				Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)			
Element	Limits 1.0J Target ppm (µg/g)	Result IPA RM Lot: RMAT-0422- 0059 ppm (µg/g)	Result IPA RM Lot: RMAT-0522- 0002 ppm (µg/g)	Result IPA RM Lot: RMAT-0722- 0056 ppm (µg/g)	Result IPA RM Lot: RMAT-1022- 0029 ppm (µg/g)	Result RM Lot: IHCL-0122- 00013-PV Reprocessed ppm (µg/g)	Result IP Lot: IHCL-0122- 00013-PV Confirmation #2 Sample ppm (µg/g)
Ag	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Pt	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Li	25	<2.5	<2.5	<2.5	<2.5	<2.5	<2.5
Sb	9.0	<0.90	<0.90	<0.90	<0.90	<0.90	<0.90
Ba	70	<7.0	<7.0	<7.0	<7.0	<7.0	<7.0
Mo	150	<15	<15	<15	<15	<15	<15
Cu	30	<3.0	<3.0	<3.0	<3.0	<3.0	<3.0
Sn	60	<6.0	<6.0	<6.0	<6.0	<6.0	<6.0
Cr	110	<11	<11	<11	<11	<11	<11
Ca	50	6.5	<5.0	5.9	<5.0	9.5	<5.0
Fe	3.0	<0.30	<0.30	<0.30	<0.30	2.1	2.2
Na	50	<5.0	<5.0	<5.0	<5.0	<5.0	<5.0

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

TABLE 3: ELEMENTAL IMPURITY ASSESSMENT				Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)			
Element	Limits 1.0J Target ppm (µg/g)	Result IP Lot: IHCL-0122- 00014-PV Confirmation #2 Sample ppm (µg/g)	Result IP Lot: IHCL-0122- 00015-PV Confirmation #2 Sample ppm (µg/g)	Result FG Lot: IHCL-0122- 00013-PV Beginning ppm (µg/g)	Result FG Lot: IHCL-0122- 00013-PV Composite ppm (µg/g)	Result FG Lot: IHCL-0122- 00014-PV Composite ppm (µg/g)	Result FG Lot: IHCL-0122- 00015-PV Composite ppm (µg/g)
Cd	0.20	<0.02	<0.02	<0.02	<0.02	<0.02	<0.02
Pb	0.50	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
As	1.5	<0.15	<0.15	<0.15	<0.15	<0.15	<0.15
Hg	0.30	<0.03	<0.03	<0.03	<0.03	<0.03	<0.03
Co	0.50	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
V	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ni	2.0	2.3	2.1	0.69	0.84	2.0	2.2
Tl	0.80	<0.08	<0.08	<0.08	<0.08	<0.08	<0.08
Au	10	<1.0	<1.0	<1.0	<1.0	<1.0	<1.0
Pd	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ir	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Os	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Rh	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Ru	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Se	8.0	<0.80	<0.80	<0.80	<0.80	<0.80	<0.80

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

TABLE 3: ELEMENTAL IMPURITY ASSESSMENT				Analytical Method: BSI-ATM-0087; Method Validation Report: BSI-RPT-0934 Manufacturing Process: BSI-PRL-0582 Degradation and Impurity Protocol: BSI-PRL-0160 Degradation and Impurity Report: BSI-RPT-1354 Parenteral Specifications (10 g/day MDD)			
Element	Limits 1.0J Target ppm (µg/g)	Result IP Lot: IHCL-0122- 00014-PV Confirmation #2 Sample ppm (µg/g)	Result IP Lot: IHCL-0122- 00015-PV Confirmation #2 Sample ppm (µg/g)	Result FG Lot: IHCL-0122- 00013-PV Beginning ppm (µg/g)	Result FG Lot: IHCL-0122- 00013-PV Composite ppm (µg/g)	Result FG Lot: IHCL-0122- 00014-PV Composite ppm (µg/g)	Result FG Lot: IHCL-0122- 00015-PV Composite ppm (µg/g)
Ag	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Pt	1.0	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
Li	25	<2.5	<2.5	<2.5	<2.5	<2.5	<2.5
Sb	9.0	<0.90	<0.90	<0.90	<0.90	<0.90	<0.90
Ba	70	<7.0	<7.0	<7.0	<7.0	<7.0	<7.0
Mo	150	<15	<15	<15	<15	<15	<15
Cu	30	<3.0	<3.0	<3.0	<3.0	<3.0	<3.0
Sn	60	<6.0	<6.0	<6.0	<6.0	<6.0	<6.0
Cr	110	<11	<11	<11	<11	<11	<11
Ca	50	<5.0	<5.0	<5.0	5.3	<5.0	<5.0
Fe	3.0	6.5	3.0	3.1	3.9	7.0	3.8
Na	50	<5.0	<5.0	<5.0	<5.0	<5.0	<5.0

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.